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The advent of clinical multimodality imaging with the development of Positron 
Emission Tomography (PET) / Computed Tomography (CT) scanners [1] has 
presented us with ample opportunities in harvesting the benefits of combining 
functional and anatomical imaging. These benefits concern improved PET 
quantitative accuracy, overall patient management (improved diagnostic accuracy 
and therapy response assessment), but also increased patient throughput. It is 
indeed this latter point that has substantially contributed to the rapid acceptance of 
PET/CT imaging in clinical practice eclipsing PET only systems. Indeed one of the 
major reasons behind the improved patient throughput achieved with PET/CT has 
been the use of CT images for the attenuation correction (AC) of the acquired PET 
emission datasets. Within this context CT images possess two desirable properties. 
Firstly, CT acquisitions are very fast, removing the need for long  radionuclide based 
transmission imaging that was traditionally used in PET (~50% of the overall 
acquisition times). Secondly, CT intensity values represent the attenuation properties 
of the tissues in the imaging field of view, albeit at X-ray photon energies. The 
necessary transformation of CT images into attenuation maps at 511keV can be 
obtained through a bilinear transformation [2].  Although such a transformation 
represents a certain approximation, CT based AC of PET datasets using such 
attenuation maps has been shown to lead to the same level of quantitative accuracy 
and superior contrast in the reconstructed PET images compared to radionuclide 
based transmission scanning [3].   
 
In the last couple of years clinical PET/MR devices have become reality and the first 
results concerning their potential interest in terms of patient management are 
beginning to emerge. Different issues however persist with respect to the quantitative 
accuracy of this new modality, concerning in particular the question of PET 
attenuation correction based on the use of MR derived attenuation maps. A recent 
study published in this journal clearly reinforces these issues for neurological imaging 
[4]. In contrast to CT imaging, MRI does not provide direct information concerning 
tissue attenuation properties and as such there is no direct way to obtain the required 
information for PET attenuation correction purposes. Most of the approaches 
currently proposed in clinical PET/MR systems for PET AC are based on the 
combination of specific MR sequences and subsequent image segmentation.  
 
Amongst them the approach implemented in the first generation of clinical systems is 
based on the two-point Dixon gradient echo sequence [5]. This sequence, which 
involves a few seconds of acquisition time, allows the separation of water and fat 
tissue by using the chemical shift of fat relative to water. This information facilitates in 
turn the segmentation of MR images in four to five different classes (lung, fat tissue, 
non-fat tissue, mixture of fat/non-fat tissue, air) [6]. One has to highlight that once 
segmented, fixed 511keV linear attenuation coefficients (LACs) are assigned to each 
of the considered tissue types, largely ignoring tissue heterogeneities. However, the 
biggest drawback of this approach is the lack for consideration of bone structures 
which are considered as soft tissue for the purpose of reconstructing PET AC maps. 
As such the use of this approach may introduce severe quantitative errors depending 
clearly on the location of the region of interest. In terms of quantitative accuracy it is 
generally accepted that the inclusion of bone in the attenuation correction of brain 
PET images is essential. On the other hand, the inclusion of bone structures in whole 
body imaging introduces quantitative errors mostly in the case of osseous lesions. 
Compared to CT based attenuation correction in whole body PET/MR imaging 
standardised uptake value (SUV) underestimation may vary from few percent up to 
30% depending not only on the lesion location but also on the composition of bone 
lesions [7]. This result further highlights the need for using a continuous scale in the 
LACs rather than a fixed value assigned in segmented tissue regions. In the case of 
brain imaging, a recent publication in EJNMMI [4] has also shown variable mean 
regional activity concentration underestimation of 10%-22% compared to CT based 
attenuation correction, with the smaller differences measured in structures such as 
the striatum, thalamus and hippocampus.        
 
In order to account and improve the overall accuracy of segmentation based 
attenuation correction, more recent implementations of PET AC in clinical PET/MR 
consider the use of an ultrashort echo time (UTE) sequence [8]. UTE sequences 
have been proposed in MRI for the visualisation of bone which has a very short spin-
spin relaxation time T2. UTE based attenuation correction involves acquisitions at 
two echo times; one visualising bone while the signal for other tissue types is the 
same in both images. Different methodologies have been subsequently proposed in 
order to provide a three tissue class (air, soft tissue, bone) segmentation approach 
for PET AC [9] or alternatively use a triple-echo sequence combining UTE and Dixon 
to distinguish four tissue classes (air, soft tissue, bone, fat tissue) [10]. These 
approaches have been almost exclusively evaluated in brain imaging showing mean 
activity concentration differences in the entire brain of ~5% relative to CT based AC, 
although maximum differences could be up to 20-40% [8,9,10]. Similarly, a more 
detailed study on a region by region basis, considering 25 FDG PET brain patients, 
has shown that despite a decrease in the measured mean activity underestimation 
resulting from the use of a three tissue class UTE based approach compared to 
Dixon based AC, there are still substantial underestimations compared to CT based 
AC. These differences (up to an average of 20%) were also region dependent, with 
the worst results at the level of the cerebellum which is located at the level of 
sinuses, where the mixture of air, soft tissue and bone structures represents a 
substantial challenge for all approaches, including UTE. In general terms average 
percentage differences of 10%-15% relative to CT based AC were measured in the 
frontal, temporal and parietal lobes. This regional variability in the measured 
differences throughout the brain is a clear issue for neurological applications. 
Furthermore, there seems to be a lack of standardisation with respect to the UTE 
protocols for AC currently in use both in terms of overall acquisition times and 
selection of individual parameters. On the other hand, there are only few reports on 
the use of UTE sequences in whole body MR imaging, since its application is 
hampered by long acquisition times and field inhomogeneities associated with an 
extended field of view. Therefore the extension of this approach for whole body 
imaging represents real challenges.    
     
There is therefore a clear need for improved AC in PET/MR not only for neurological 
but also whole body imaging applications. This improvement should be both in terms 
of accuracy in determining the spatial extent of the structures of interest but also in 
the use of attenuation maps with continuous LACs. There are different approaches 
based on the use of atlas combined with machine learning techniques that have been 
proposed in order to improve both of these aspects. The basic idea behind these 
approaches is to explore a database of paired CT and MR patient images. These 
images in combination with the acquired MR datasets for a given patient are 
subsequently used in order to derive a patient specific pseudo-CT map. Another 
advantage for these approaches is that in principle can provide attenuation maps 
with continuous LACs, eliminating issues associated with the use of single tissue 
values that do not account for tissue heterogeneities. Different MR sequences can be 
considered in the MR-CT paired datasets used in the atlas in order to improve the 
overall accuracy of the identified structures of interest. One of these approaches uses 
a combination of atlas derived information and pattern recognition to obtain patient 
specific pseudo-CT maps [11]. This approach has been evaluated in brain images 
showing average activity concentration differences of <4% relative to CT based AC in 
different brain areas without reporting on inter-regional differences. A clear issue with 
any atlas based approach for brain and whole body applications is the accurate 
handling of pathology, inter-patient lung density variations, or the presence of 
metallic implants. In an attempt to improve overall robustness, a modified version of 
this same approach including atlas based artefacts detection, has been more recently 
applied to whole body imaging leading to mean activity underestimations of <6% [12]. 
Variants of this approach consider the use of multiple MR sequences in order to 
better identify different tissues classes and hence improve the overall atlas 
registration process and the subsequent pseudo-CT prediction model [13,14]. 
Although such alternatives have been only tested on brain imaging, since they mostly 
use UTE sequences, they are clearly associated with longer MR acquisition times 
which may compromise their clinical utility in PET/MR. What is currently missing is 
large scale clinical evaluation studies for these atlas and machine learning 
approaches in order to clearly demonstrate their robustness with respect to the 
presence of anatomical abnormalities which are largely patient specific and as such 
hard to account for in any atlas based approach.  
 
One has to finally consider the truncation issues associated with MR based 
attenuation correction maps which can be important in whole body imaging given that 
the patients are scanned arms down due to multiple practical issues. Different 
solutions have already been implemented on current generation PET/MR devices 
based either on information from uncorrected PET images [15] or using a modified 
iterative maximum likelihood reconstruction of attenuation and activity (MLAA) for 
estimating the missing part of the attenuation map from the PET emission data [16]. 
Despite the lack of resolution in bone structures in the arms, both approaches have 
been reported to reduce errors to <5%, but clearly larger scale clinical studies are 
necessary to demonstrate their performance and associated robustness in clinical 
practice. On the other hand, both approaches will clearly benefit from time of flight 
(ToF) information improving further their accuracy.    
 
An alternative that has more recently emerged is the use of non-MR information for 
PET AC in PET/MR. The first such approach is based on the use of transmission 
scanning within the PET/MR device [17], using radionuclide sources and the 
acquisition of both emission and transmission datasets during the PET acquisition. In 
order to be able to carry out such simultaneous acquisitions the PET device requires 
ToF capabilities. Although theoretically feasible, the question of limited space 
available with combined PET/MR devices poses certain associated engineering 
challenges for the clinical implementation of such an approach, which may therefore 
be more appropriate for sequential PET/MR systems only. The second option is 
based on purely exploring information inherent in the acquired PET emission 
datasets about tissue attenuation without the need for any explicit transmission data 
acquisition. If one assumes that the true emission data distribution is known there will 
be only a single attenuation map that can be consistent with that emission distribution 
and can be therefore estimated. However, the problem is poorly determined and as 
such previous attempts have led to poor results with emission data structures 
contained in the estimated attenuation correction maps. More recently Defrise et al 
[18] have demonstrated that the spatial constraints provided by the ToF information 
in the emission datasets may allow a more robust exploitation of the consistency 
conditions in order to determine the attenuation images from the acquired emission 
datasets. Despite the fact that current devices are limited in terms of ToF resolution 
to 400-500ps, this study has also shown that this ToF resolution is sufficient to obtain 
good results for clinical applications. Although this initial proof of principle work was 
performed in 2D using an analytical algorithm, current studies in this active field are 
concentrating on an extension to 3D and the use of iterative algorithms that allows 
better noise modelling [19].     
 
In conclusion, the development of combined PET/MR devices has brought to the 
forefront of scientific interest the issue of PET attenuation correction, after CT largely 
contributed to its solution in multimodality PET/CT imaging. Current clinical AC 
implementations are moving towards the inclusion of bone structures which are 
clearly essential in quantitative neurological PET imaging, in principle one of the 
flagship applications of PET/MR. However, substantial quantitative differences 
compared to CT based AC persist, which appear to be also region dependent with 
the largest differences in areas at the vicinity of dense bone and/or a substantial 
mixture of bone, air and soft tissue. There is now clearly a need for larger patient 
population studies with protocol standardisation in the MR sequence parameters 
used in order to further evaluate these latest developments for quantitative brain 
imaging in clinical practice. Atlas and machine learning approaches offer the 
possibility to correct for AC including bone structures both in brain and whole body 
PET/MR applications. However, these approaches need also to be further assessed 
in clinical practice in order to demonstrate their robustness to different patient specific 
pathology types. Finally, the calculation of attenuation maps directly from emission 
datasets is the most promising solution for future ToF based PET/MR devices.        
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